Novo Nordisk, obesity

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.